We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




United Kingdom to Build a New Cell and Gene Therapy Manufacturing Center

By LabMedica International staff writers
Posted on 04 Jan 2015
The United Kingdom (UK) Cell Therapy Catapult (Guy's Hospital; Great Maze Pond, London, UK) plans to build the new GBP 55-million Cell Therapy manufacturing center in the Stevenage Bioscience Catalyst campus (Stevenage, UK). More...


Cell therapy and gene therapy use a patient's own cells to fight or prevent diseases such as cancer, and can replace the use of drugs or surgery.

The center which will open in 2017, is forecast to generate investment by international companies of GBP 1.2 billion (80% via export) by the year 2020, and up to 150 new jobs. The center will manufacture commercial supplies of advanced therapeutic medicinal products such as gene and cell therapies, as well as late-phase clinical trial equipment. The Cell Therapy Catapult will manage the center.

According to Iain Gray, Chief Executive of United Kingdom Government's Innovate UK (Swindon, Wiltshire, UK), “This is an exciting development for the Cell Therapy Catapult and an important next step in the establishment of the UK as a global manufacturing center for the cell therapy industry.”

Related Links:
Stevenage Bioscience Catalyst campus
Cell Therapy Catapult
Innovate UK



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.